Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?

The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Habtemariam, Solomon, Nabavi, Seyed Fazel, Banach, Maciej, Berindan-Neagoe, Ioana, Sarkar, Kasturi, Sil, Parames C., Nabavi, Seyed Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IMSS. Published by Elsevier Inc. 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261434/
https://www.ncbi.nlm.nih.gov/pubmed/32536457
http://dx.doi.org/10.1016/j.arcmed.2020.05.024
Descripción
Sumario:The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins. Highlighting the experience gained from targeting Nsp13 in similar coronaviruses (SARS-CoV and MERS) and known inhibitors, the article calls for research on helicase inhibitors as potential COVID-19 therapy.

Ejemplares similares